Statera Biopharma Submits Phase I Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

Statera Biopharma, Inc. announced submission to the FDA of its pilot study protocol for STAT-205 treatment of post-acute COVID-19.